TalkMed Group says that it has received "interest" from "persons" who are considering the acquisition of a stake in the company.
"The discussions are preliminary at this stage and there is no assurance that a transaction will take place," says the company on April 6.
TalkMed, a specialist cancer medical group, is controlled by group CEO Dr Ang Peng Tiam, who has an interest in 64.74% of the shares. Group COO Dr Khoo Kei Siong holds another 7.49%.
On Feb 20, the company reported earnings of $32.7 million for FY2023, up 9.7% over the preceding year ended Dec 31 2022. Revenue in the same period was up 9.4% to $83.8 million, due to higher patient numbers.
Despite the better earnings, Talkmed is paying a lower dividend of 1.3 cents for FY2023, down from 1.5 cents paid for FY2022.
TalkMed was listed back in 2014, with its IPO shares offered at 20 cents each. It surged to an all-time high of 89 cents in 2017.
See also: Nissan CFO set to step down as carmaker faces raft of challenges
TalkMed shares closed at 38 cents on April 5 and with FY2023 EPS of 2.43 cents, values the company at 15.6x historical earnings.
